TY - JOUR
T1 - Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction
T2 - Evolution toward prospective theranostic approaches
AU - Bejarano, Julian
AU - Navarro-Marquez, Mario
AU - Morales-Zavala, Francisco
AU - Morales, Javier O.
AU - Garcia-Carvajal, Ivonne
AU - Araya-Fuentes, Eyleen
AU - Flores, Yvo
AU - Verdejo, Hugo E.
AU - Castro, Pablo F.
AU - Lavandero, Sergio
AU - Kogan, Marcelo J.
N1 - Funding Information:
This work was supported by Comisión Nacional de Investigación Científica y Tecnológica (CONICYT), Chile, Fondo de Financiamiento Centros de Excelencia en Investigación en Áreas Prioritarias (FONDAP) grant 15130011 (to. S.L., M.K., P.F.C., H.E.V. F.M.Z and J.O.M) and Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) grants 1170929 (to M.K.) and 1181689 (to J.O.M). J.B. was supported by post-doctoral FONDECYT grants 3160323. M.N-M and I.G-C are recipients of a Ph.D. fellowship from CONICYT. EA acknowledges Proyecto Nucleo DI-36-18/N.
Publisher Copyright:
© Ivyspring International Publisher.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Cardiovascular diseases are the leading cause of death worldwide. Despite preventive efforts, early detection of atherosclerosis, the common pathophysiological mechanism underlying cardiovascular diseases remains elusive, and overt coronary artery disease or myocardial infarction is often the first clinical manifestation. Nanoparticles represent a novel strategy for prevention, diagnosis, and treatment of atherosclerosis, and new multifunctional nanoparticles with combined diagnostic and therapeutic capacities hold the promise for theranostic approaches to this disease. This review focuses on the development of nanosystems for therapy and diagnosis of subclinical atherosclerosis, coronary artery disease, and myocardial infarction and the evolution of nanosystems as theranostic tools. We also discuss the use of nanoparticles in noninvasive imaging, targeted drug delivery, photothermal therapies together with the challenges faced by nanosystems during clinical translation.
AB - Cardiovascular diseases are the leading cause of death worldwide. Despite preventive efforts, early detection of atherosclerosis, the common pathophysiological mechanism underlying cardiovascular diseases remains elusive, and overt coronary artery disease or myocardial infarction is often the first clinical manifestation. Nanoparticles represent a novel strategy for prevention, diagnosis, and treatment of atherosclerosis, and new multifunctional nanoparticles with combined diagnostic and therapeutic capacities hold the promise for theranostic approaches to this disease. This review focuses on the development of nanosystems for therapy and diagnosis of subclinical atherosclerosis, coronary artery disease, and myocardial infarction and the evolution of nanosystems as theranostic tools. We also discuss the use of nanoparticles in noninvasive imaging, targeted drug delivery, photothermal therapies together with the challenges faced by nanosystems during clinical translation.
KW - Atherosclerosis
KW - Cardiovascular diseases
KW - Myocardial infarction
KW - Nanoparticles
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85053130172&partnerID=8YFLogxK
U2 - 10.7150/thno.26284
DO - 10.7150/thno.26284
M3 - Article
AN - SCOPUS:85053130172
SN - 1838-7640
VL - 8
SP - 4710
EP - 4732
JO - Theranostics
JF - Theranostics
IS - 17
ER -